An official website of the United States government
Improving Screening for Patients at High Risk for Pancreas Cancer using Magnetic Resonance CholangioPancreatography and Endoscopic Ultrasound
Trial Status: active
This clinical trial is being done to improve screening for patients at high risk for pancreas cancer using magnetic resonance cholangiopancreatography (MRCP) and endoscopic ultrasound (EUS). MRCP is a magnetic resonance imaging (MRI) scan that uses magnets and radio waves to create detailed 3D images of the pancreas, bile ducts, liver, and gall bladder. MRCP is used to diagnose blockages, tumors, gallstones, and inflammation. An EUS uses an endoscope, a thin, tube-like instrument that has an ultrasound device (probe) on the tip to bounce high energy soundwaves (ultrasound) off internal organs to create images of the digestive tract and other organs like the pancreas. Researchers want to see whether a dedicated MRI scan of the pancreas (MRP) can provide better images of the pancreas compared to MRCP. MRP is an MRI scan that focuses just on the pancreas. The researchers think this could help detect pancreatic cancer at an earlier stage.
Inclusion Criteria
Must meet one or more high-risk criteria:
* Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual
* Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer
* Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2
Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+
Consents to follow-up contact
United States (US) residents
Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass)
No metallic artifacts covering the pancreas on prior MRCP
Scheduled for endoscopic ultrasound
No new contraindications for MRI (e.g. new MR unsafe device)
No history of claustrophobia or use of anxiolytic on prior MRI
No history of abdominal surgery that may affect interpretation of either EUS or MR
No medical conditions that confers increased and/or unacceptable risk for anesthesia
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07612046.
Locations matching your search criteria
United States
New Jersey
Basking Ridge
Memorial Sloan Kettering Basking Ridge
Status: Active
Contact: Kinh Gian (Richard) Do
Phone: 212-639-8591
Middletown
Memorial Sloan Kettering Monmouth
Status: Active
Contact: Kinh Gian (Richard) Do
Phone: 212-639-8591
Montvale
Memorial Sloan Kettering Bergen
Status: Active
Contact: Kinh Gian (Richard) Do
Phone: 212-639-8591
New York
Commack
Memorial Sloan Kettering Commack
Status: Active
Contact: Kinh Gian (Richard) Do
Phone: 212-639-8591
New York
Memorial Sloan Kettering Cancer Center
Status: Active
Contact: Kinh Gian (Richard) Do
Phone: 212-639-8591
Uniondale
Memorial Sloan Kettering Nassau
Status: Active
Contact: Kinh Gian (Richard) Do
Phone: 212-639-8591
West Harrison
Memorial Sloan Kettering Westchester
Status: Active
Contact: Kinh Gian (Richard) Do
Phone: 212-639-8591
PRIMARY OBJECTIVE:
I. Develop and pilot a focused high-resolution magnetic resonance pancreas (MRP) exam to help facilitate early pancreatic cancer detection in high-risk individuals.
OUTLINE:
Patients undergo MRCP and EUS on study.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationMemorial Sloan Kettering Cancer Center
